Cognate Bioservices, Inc.;Revlmmune, Inc.;Northwest Biotherapeutics, Inc.; Inc.;Revlmmune;The Regents of the University of California
发明人:
Bosch, Marnix Leo,Ganjei, James Kelly,Powers, Linda F.,Liau, Linda M.,Prins, Robert M.
申请号：
AU2014346852
公开号：
AU2014346852A1
申请日:
2014.11.05
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
